Table 2.

Information of the grafts

Patient	Salvage alloBMT	Prior BMT	Same donor as previous BMT	Salvage graft	CD34+/kg	CD3+	Patient/donor ABO
1	Second transplant	BU/CYa MUD BMT	Yes	MUD BM	4.90E + 06b	NA	A + /O +
2	Second transplant	CY/TBI HLA identical sibling BMTc	Yes	Allo PBSC	5.63E + 06	2.10E + 08	A + /A +
3	Second transplant	BU/CY HLA identical sibling BMTa	Yes	Allo PBSC	5.46E + 06	4.10E + 08	O + /B +
4	Second transplant	BU/CY HLA identical sibling BMTd	Yes	Allo PBSC	2.61E + 07	9.93E + 08	A + /A−
5	Second transplant	BU/CY HLA identical sibling BMTe	Yes	Allo PBSC	2.31E + 06	2.33E + 08	A + /O +
6	Second transplant	BU/CY HLA identical sibling BMTd	No	Allo PBSC	2.56E + 06	4.45E + 08	B + /B +
7	Third transplant	Flu/CY/TBI haploBMTf; then BU/CYd MUD BMT	Yes (different from 1st BMT)	MUD PBSC	9.35E + 06	4.69E + 08	O + /O +
8	Second transplant	BU/CYd MUD BMT	Yes	MUD PBSC	7.58E + 06	5.65E + 08	B + /O +
9	Second transplant	BU/CYd MUD BMT	Yes	MUD PBSC	3.60E + 08	2.37E + 07	O−/O +

Abbreviations: Allo = allogeneic; Flu = fludarabine; haplo = haploidentical; MUD = matched unrelated donor.

^aBU (16 mg/kg) plus CY (200 mg/kg) as described by Santos et al.²⁴

^bNucleated cells/kg.

^cCY (200 mg/kg) plus TBI 1200 cGy as described by Wingard et al.²⁵

^dBU (16 mg/kg), CY (100 mg/kg) plus post transplant CY (100 mg/kg) as described by Luznik et al.²⁶

^eBU (16 mg/kg) plus CY (200 mg/kg) with T-cell-depleted graft.

^fFludarabine (120 mg/m²), CY (29 mg/kg), TBI 200 cGy, plus post transplant CY (100 mg/kg) as described by Luznik et al.²⁷